Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

Collaboration aims to identify and validate novel targets with strong genetic evidence and clear therapeutic hypotheses The partnership between Novo Nordisk and Variant Bio is aimed at identifying ...

On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with the drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.

Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...

Under the terms of the agreement, Novo Nordisk will pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments ...